TABLE OF CONTENTS
Volume 19, Issue 1 (January 2005)
Reviews |
Spotlight on Imatinib as a Model for Signal Transduction Inhibitors |
Commentary |
Original Manuscripts |
Bio-Technical Methods Section (BTS) |
Spotlight Correspondence |
Correspondence
Leading Articles
Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation
M Mohty, D Blaise, C Faucher, V-J Bardou, J-A Gastaut, P Viens, D Olive and B Gaugler
Leukemia 19: 1-6; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403558
Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning
A Shimoni, N Kröger, T Zabelina, F Ayuk, I Hardan, M Yeshurun, N Shem-Tov, A Avigdor, I Ben-Bassat, A R Zander and A Nagler
Leukemia 19: 7-12; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403591
Reviews
Is physical fitness decreased in survivors of childhood leukemia? A systematic review
M van Brussel, T Takken, A Lucia, J van der Net and P J M Helders
Leukemia 19: 13-17; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403547
Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors
K E Hamden, A G Whitman, P W Ford, J G Shelton, J A McCubrey and S M Akula
Leukemia 19: 18-26; advance online publication, October 7, 2004; doi:10.1038/sj.leu.2403532
Spotlight on Imatinib as a Model for Signal Transduction Inhibitors
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)
R L Levine, M Wadleigh, D W Sternberg, I Wlodarska, I Galinsky, R M Stone, D J DeAngelo, D Gary Gilliland and J Cools
Leukemia 19: 27-30; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403548
Commentary
Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?
K van Besien, A Artz and W Stock
Leukemia 19: 31-33; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403594
Original Manuscripts
Therapy
Efficacy and safety of rasburicase, a recombinant urate oxidase (ElitekTM), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial
S Jeha, H Kantarjian, D Irwin, V Shen, S Shenoy, S Blaney, B Camitta and C-H Pui
Leukemia 19: 34-38; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403566
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia
R T Silver
Leukemia 19: 39-43; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403556
ALL
Immunosurveillance of childhood ALL: polymorphic interferon-
alleles are associated with age at diagnosis and clinical risk groups
T Cloppenborg, M Stanulla, M Zimmermann, M Schrappe, K Welte and C Klein
Leukemia 19: 44-48; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403553
Minimal Residual Disease
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection
G Gaipa, G Basso, O Maglia, V Leoni, A Faini, G Cazzaniga, C Bugarin, M Veltroni, B Michelotto, R Ratei, T Coliva, M G Valsecchi, A Biondi and M N Dworzak on behalf of the I-BFM-ALL-FCM-MRD-Study Group
Leukemia 19: 49-56; advance online publication, November 11, 2004; doi:10.1038/sj.leu.2403559
Myelodysplasias
CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of 
4
1 and 51 integrins
M Delforge, V Raets, V Van Duppen, P Vandenberghe and M Boogaerts
Leukemia 19: 57-63; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403551
CLL
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells
M Molina-Arcas, S Marcé, N Villamor, I Huber-Ruano, F J Casado, B Bellosillo, E Montserrat, J Gil, D Colomer and M Pastor-Anglada
Leukemia 19: 64-68; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403582
Immunophenotypes
Phenotype and function of a CD56+ peripheral blood monocyte
G Sconocchia, K Keyvanfar, F El Ouriaghli, M Grube, K Rezvani, H Fujiwara, J P McCoy Jr, N Hensel and A J Barrett
Leukemia 19: 69-76; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403550
Cytogenetics
Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in 'unmutated' B-CLL
L Michaux, I Wlodarska, K Rack, M Stul, A Criel, M Maerevoet, S Marichal, H Demuynck, P Mineur, K Kargar Samani, A Van Hoof, A Ferrant, P Marynen and A Hagemeijer
Leukemia 19: 77-82; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403543
BMT and Stem Cells
Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFN-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion
F M Kloosterboer, S A P van Luxemburg-Heijs, R A van Soest, H M van Egmond, A M Barbui, M P W Strijbosch, R Willemze and J H F Falkenburg
Leukemia 19: 83-90; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403572
Multipotent neural precursors express neural and hematopoietic factors, and enhance ex vivo expansion of cord blood CD34+ cells, colony forming units and NOD/SCID-repopulating cells in contact and noncontact cultures
K Li, S M Lee, R J Su, X B Zhang, P M P Yuen, C K Li, M Yang, K S Tsang, A E James, Y H J Tse, L Y W Ng and T F Fok
Leukemia 19: 91-97; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403542
Signal Transduction
Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support
F E Bertrand, J D Spengemen, J G Shelton and J A McCubrey
Leukemia 19: 98-102; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403560
DNA Methylation
Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms FREE
K Schmelz, N Sattler, M Wagner, M Lübbert, B Dörken and I Tamm
Leukemia 19: 103-111; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403552
Lymphoma
Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms
F Tort, S Hernández, S Beà, E Camacho, V Fernández, M Esteller, M F Fraga, C Burek, A Rosenwald, L Hernández and E Campo
Leukemia 19: 112-117; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403571
Myeloma
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
A Dispenzieri, G A Wiseman, M Q Lacy, M R Litzow, P M Anderson, D A Gastineau, A Tefferi, D J Inwards, I N M Micallef, S M Ansell, L Porrata, M A Elliott, J A Lust, P R Greipp, S V Rajkumar, R Fonseca, T E Witzig, C Erlichman, J A Sloan and M A Gertz
Leukemia 19: 118-125; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403575
Bio-Technical Methods Section (BTS)
Development of a D-FISH method to detect DEK/CAN fusion resulting from t(6;9)(p23;q34) in patients with acute myelogenous leukemia
B M Shearer, R A Knudson, H C Flynn and R P Ketterling
Leukemia 19: 126-131; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403557
Spotlight Correspondence
Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib
R G Piazza, V Magistroni, M Gasser, F Andreoni, A Galietta, L Scapozza and C Gambacorti-Passerini
Leukemia 19: 132-134; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403453
Correspondence
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia
P P Piccaluga, G Martinelli, M Malagola, M Rondoni, F Bonifazi, G Bandini, G Visani and M Baccarani
Leukemia 19: 135; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403578
Reply to Piccaluga et al
J-P Laporte, F Isnard, L Fouillard, L Garderet and N-C Gorin
Leukemia 19: 136; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403579
Bedside RNA stabilizing kit systems for gene expression analysis of acute leukemias: influence of non-neoplastic white blood cells
A Zebisch, W Linkesch and H Sill
Leukemia 19: 136-137; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403581
Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9
T Lundán, L Volin, T Ruutu, S Knuutila and K Porkka
Leukemia 19: 138-140; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403570
Novel mutations in the FLT3 gene in adult patients with refractory acute myeloid leukemia
Y Choi, H-J Kim, B-H Park, W-S Min and C-C Kim
Leukemia 19: 141-143; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403580
Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas
K L Wu, H H Helgason, B van der Holt, P W Wijermans, H M Lokhorst, W M Smit and P Sonneveld
Leukemia 19: 143-145; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403568
A new translocation t(9;11)(q34;p15) fuses NUP98 to a novel homeobox partner gene, PRRX2, in a therapy-related acute myeloid leukemia
C Gervais, L Mauvieux, N Perrusson, C Hélias, S Struski, V Leymarie, B Lioure and M Lessard
Leukemia 19: 145-148; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403565
Overexpression of HOXB4 confers a myelo-erythroid differentiation delay in vitro
M D Milsom, R Duxbury, D Gagen, R K Humphries, M Schmidt, C von-Kalle and L J Fairbairn
Leukemia 19: 148-153; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403554
Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia
L Laurenti, P Piccioni, M Tarnani, P Chiusolo, N Piccirillo, C Rumi, F Sora, S Sica and G Leone
Leukemia 19: 153-154; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403561
Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma
M J Borad, R Swift and J R Berenson
Leukemia 19: 154-156; advance online publication, October 21, 2004; doi:10.1038/sj.leu.2403541
Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma
R Fenk, B Hoyer, U Steidl, M Kondakci, T Graef, R Heuk, L Ruf, C Strupp, F Neumann, U-P Rohr, B Hildebrandt, R Haas and G Kobbe
Leukemia 19: 156-159; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403564
Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line
M B Karpova, J Schoumans, I Ernberg, J-I Henter, M Nordenskjöld and B Fadeel
Leukemia 19: 159-161; advance online publication, September 30, 2004; doi:10.1038/sj.leu.2403534
Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells
M Bornhäuser, L Eger, U Oelschlaegel, S Auffermann-Gretzinger, A Kiani, J Schetelig, T Illmer, M Schaich, D Corbeil, C Thiede and G Ehninger
Leukemia 19: 161-165; advance online publication, October 28, 2004; doi:10.1038/sj.leu.2403563
Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia
B M Frost, E Forestier, G Gustafsson, P Nygren, M Hellebostad, G Jonmundsson, J Kanerva, K Schmiegelow, R Larsson and G Lönnerholm On behalf of the Nordic Society for Paediatric Haematology and Oncology
Leukemia 19: 165-169; advance online publication, November 4, 2004; doi:10.1038/sj.leu.2403540
